Comparison 2. Dosages.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Maximum percent decrease in FEV‐1	7	194	Mean Difference (IV, Fixed, 95% CI)	‐0.88 [‐4.49, 2.74]
1.1 NCS 4 mg. vs SCG 10 mg.	5	138	Mean Difference (IV, Fixed, 95% CI)	‐0.18 [‐4.38, 4.01]
1.2 NCS 4 mg. vs SCG 20 mg.	1	24	Mean Difference (IV, Fixed, 95% CI)	2.20 [‐7.78, 12.18]
1.3 NCS 8 mg. vs SCG 4 mg.	1	32	Mean Difference (IV, Fixed, 95% CI)	‐8.26 [‐18.52, 2.00]
2 Failure to achieve Complete Protection: Maximum % fall >10%	6	156	Odds Ratio (M‐H, Random, 95% CI)	0.95 [0.50, 1.81]
2.1 NCS 4 mg. vs SCG 10 mg.	4	100	Odds Ratio (M‐H, Random, 95% CI)	0.85 [0.39, 1.88]
2.2 NCS 4 mg. vs SCG 20 mg.	1	24	Odds Ratio (M‐H, Random, 95% CI)	2.0 [0.38, 10.41]
2.3 NCS 8 mg. vs SCG 4 mg.	1	32	Odds Ratio (M‐H, Random, 95% CI)	0.73 [0.16, 3.45]
3 Failure to achieve Complete Protection: Maximum % fall >15%	6	170	Odds Ratio (M‐H, Random, 95% CI)	0.69 [0.33, 1.47]
3.1 NCS 4 mg. vs SCG 10 mg.	5	138	Odds Ratio (M‐H, Random, 95% CI)	0.89 [0.44, 1.81]
3.2 NCS 4 mg. vs SCG 20 mg.	0	0	Odds Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.3 NCS 8 mg. vs SCG 4 mg.	1	32	Odds Ratio (M‐H, Random, 95% CI)	0.2 [0.04, 0.91]
4 Failure to achieve Clinical Protection: <50% improvement over placebo	6	156	Odds Ratio (M‐H, Random, 95% CI)	0.71 [0.36, 1.39]
4.1 NCS 4 mg. vs SCG 10 mg.	4	100	Odds Ratio (M‐H, Random, 95% CI)	0.76 [0.32, 1.79]
4.2 NCS 4 mg. vs SCG 20 mg.	1	24	Odds Ratio (M‐H, Random, 95% CI)	1.0 [0.20, 5.07]
4.3 NCS 8 mg. vs SCG 4 mg.	1	32	Odds Ratio (M‐H, Random, 95% CI)	0.47 [0.11, 1.92]